Effect of pioglitazone on the course of new-onset type 1 diabetes mellitus
Kimberly Sue Tafuri, Mushtaq Ahmed Godil, Andrew Harry Lane, Thomas Allen Wilson, Kimberly Sue Tafuri, Mushtaq Ahmed Godil, Andrew Harry Lane, Thomas Allen Wilson
Abstract
Objective: Type 1 diabetes mellitus (T1DM) is caused by insulin deficiency resulting from progressive destruction of β cells. The histological hallmark of the diabetic islet is mononuclear cell infiltration. Thiazolidinediones (TZDs) activate PPARg and enhance the actions of insulin. Studies in non-obese diabetic and streptocotozin-treated mouse models demonstrated that pretreatment with TZDs prevented the development of T1DM. The purpose of this study was to examine whether pioglitazone, given with insulin, preserved β cell function in patients with new-onset T1DM.
Methods: This was a randomized, double-blind, placebo-controlled 24-week study. Subjects received pioglitazone or placebo. Blood sugar, glycated hemoglobin (HbA1c), C-peptide, and liver enzymes were measured at baseline. Boost© stimulated C-peptide responses were measured at baseline and at 24 weeks. Blood sugar, insulin dose, height, weight, and liver enzymes were monitored at each visit. HbA1c was performed every 12 weeks.
Results: Of the 15 patients, 8 received pioglitazone, and 7 - placebo. There was no clinical improvement in HbA1c between or within groups at the completion of the study. Mean peak C-peptide values were similar between groups at baseline. Mean peak C-peptide level was slightly higher at 24 weeks in the pioglitazone group compared to the placebo (1.8 vs. 1.5 ng/mL) which was considered as clinically insignificant. The interaction of HbA1c and insulin dose (HbA1c* insulin/kg/day), which combines degree of diabetic control and dose of insulin required to achieve this control, showed transient improvement in the pioglitazone group at 12 weeks but was not sustained at 24 weeks.
Conclusion: In this pilot study, pioglitazone did not preserve β cell function when compared to placebo.
Trial registration: ClinicalTrials.gov NCT00545857.
Figures
References
- Schranz DB, Lernmark A. Immunology in diabetes: an update. Diabetes Metab Rev. 1998;14:3–29.
- Bertera S, Alexander A, Giannoukakis N, Robbins PD, Trucco M. Immunology of type 1 diabetes. Intervention and prevention strategies. Endocrinol Metab Clin North Am. 1999;28:841–864.
- Bottazzo GF, Dean BM, McNally JM, MacKay EH, Swift PG, Gamble DR. In situ characterization of autoimmune phenomena and expression of HLA molecules in the pancreas in diabetic insulitis. N Engl J Med. 1985;313:353–360.
- Itoh N, Hanafusa T, Miyazaki A, Miyagawa J, Yamagata K, Yamamoto K, Waguri M, Imagawa A, Tamura S, Inada M. Mononuclear cell infiltration and its relation to the expression of major histocompatibility complex antigens and adhesion molecules in pancreas biopsy specimens from newly diagnosed insulin-dependent diabetes mellitus patients. J Clin Invest. 1993;92:2313–2322.
- Ogawa J, Takahashi S, Fujiwara T, Fukushige J, Hosokawa T, Izumi T, Kurakata S, Horikoshi H. Troglitazone can prevent development of type 1 diabetes induced by multiple low-dose streptozotocin in mice. Life Sci. 1999;65:1287–1296.
- Jha R. Thiazolidinediones--the new insulin enhancers. Clin Exp Hypertens. 1999;21:157–166.
- Day C. Thiazolidinediones: a new class of antidiabetic drugs. Diabet Med. 1999;16:179–192.
- Takamura T, Ando H, Nagai Y, Yamashita H, Nohara E, Kobayashi K. Pioglitazone prevents mice from multiple low-dose streptozotocin-induced insulitis and diabetes. Diabetes Res Clin Pract. 1999;44:107–114.
- Ishida H, Takizawa M, Ozawa S, Nakamichi Y, Yamaguchi S, Katsuta H, Tanaka T, Maruyama M, Katahira H, Yoshimoto K, Itagaki E, Nagamatsu S. Pioglitazone improves insulin secretory capacity and prevents the loss of beta-cell mass in obese diabetic db/db mice: Possible protection of beta cells from oxidative stress. Metabolism. 2004;53:488–494.
- Beales PE, Pozzilli P. Thiazolidinediones for the prevention of diabetes in the non-obese diabetic (NOD) mouse model: Implications for human type 1 diabetes. Diabetes Metab Res Rev. 2002;18:114–117.
- Augstein P, Dunger A, Heinke P, Wachlin G, Berg S, Hehmke B, Salzsieder E. Prevention of autoimmune diabetes in NOD mice by troglitazone is associated with modulation of ICAM-1 expression on pancreatic islet cells and IFN-gamma expression in splenic T cells. Biochem Biophys Res Commun. 2003;304:378–384.
- Zeender E, Maedler K, Bosco D, Berney T, Donath MY, Halban PA. Pioglitazone and sodium salicylate protect human beta-cells against apoptosis and impaired function induced by glucose and interleukin-1beta. J Clin Endocrinol Metab. 2004;89:5059–5066.
- Waldron-Lynch F, Herold KC. Advances in Type 1 diabetes therapeutics: immunomodulation and beta-cell salvage. Endocrinol Metab Clin North Am. 2009;38:303–317.
- Miyazaki Y, Matsuda M, DeFronzo RA. Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes. Diabetes Care. 2002;25:517–523.
- Shigihara T, Okubo Y, Kanazawa Y, Oikawa Y, Shimada A. Thiazolidinediones may not reduce diabetes incidence in type 1 diabetes. Ann N Y Acad Sci. 2006;1079:365–368.
- Zdravkovic V, Hamilton JK, Daneman D, Cummings EA. Pioglitazone as adjunctive therapy in adolescents with type 1 diabetes. J Pediatr. 2006;149:845–849.
- Bhat R, Bhansali A, Bhadada S, Sialy R. Effect of pioglitazone therapy in lean type 1 diabetes mellitus. Diabetes Res Clin Pract. 2007;78:349–354.
- SShimada A, Shigihara T, Okubo Y, Katsuki T, Yamada Y, Oikawa Y. Pioglitazone may accelerate disease course in slowly progressive type 1 diabetes. Diabetes Metab Res Rev. 2011;27:951–953.
- Yang Z, Zhou Z, Li X, Huang G, Lin J. Rosiglitazone preserves islet beta-cell function of adult-onset latent autoimmune diabetes in 3 years follow-up study. Diabetes Res Clin Pract. 2009;83:54–60.
Source: PubMed